Rozanolixizumab
ucb pharmaceuticals
[]
the study recruited 200 adults with generalized #myastheniagravis who were anti-achr or anti-musk antibody positive and randomly assigned them 1:1:1 to weekly subcutaneous rozanolixizumab 7 mg/kg , 10 mg/kg, or placebo for 6 weeks. #aanam 
Associate editorial director, @Neurology_Live 🧠 and @CGT_Live 🧬 Host of the #MindMoments podcast 🎧 and @medicalwrldnews Deep Dive 📺